5th ADC Linker and Conjugation Summit 2027

The 5th ADC Linker and Conjugation Summit 2027 advances antibody-drug conjugate innovation through linker chemistry, conjugation technologies, dual-payload strategies, and site-specific design approaches that improve therapeutic efficacy, stability, selectivity, and safety.

Key topics

• Hydrophilic linker spacers and payload shielding technologies
• Dual-payload antibody-drug conjugates and orthogonal conjugation strategies
• Site-specific enzymatic conjugation and glycan-directed attachment methods
• Advanced linker chemistry for enhanced tumor selectivity and reduced toxicity
• Drug-to-antibody ratio optimization and high-DAR conjugate engineering
• Next-generation click chemistry and conjugation platforms
• Tumor microenvironment pharmacokinetics and pharmacodynamics
• Translational strategies for safer and more potent ADC therapies
• Novel payload integration and degradable antibody conjugates
• Conjugation stability and reduced systemic payload loss
• Analytical technologies for linker and drug design optimization
• Antibody integrity preservation and serum stability enhancement

Who should attend

• ADC research scientists and bioconjugation specialists
• Pharmaceutical and biotechnology professionals
• Medicinal chemists and linker technology developers
• Drug discovery and translational medicine researchers
• Antibody engineering and biologics experts
• Clinical development and pharmacology professionals
• Process development and manufacturing scientists
• Cancer therapeutics and oncology researchers
• Analytical chemistry and formulation specialists
• Professionals working on next-generation targeted therapies